TRIVARIS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trivaris, and what generic alternatives are available?
Trivaris is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in TRIVARIS is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trivaris
A generic version of TRIVARIS was approved as triamcinolone acetonide by TARO on October 1st, 1986.
Summary for TRIVARIS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 1 |
Patent Applications: | 4,306 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TRIVARIS at DailyMed |
Recent Clinical Trials for TRIVARIS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Nuvo Research Inc. | Phase 2 |
Injury Care Medical Center | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for TRIVARIS
US Patents and Regulatory Information for TRIVARIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | TRIVARIS | triamcinolone acetonide | INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL | 022220-001 | Jun 16, 2008 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |